

VIRAL LOAD SUPPRESSION AND ASSOCIATED FACTORS AMONG HIV-INFECTED PATIENTS ON SECOND-LINE ANTIRETROVIRAL THERAPY AT PUBLIC HEALTH FACILITIES OF WEST GUJI, GUJI AND BORENA ZONES, SOUTHERN ETHIOPIA: FACILITY BASED CROSS-SECTIONAL STUDY.

- Digafe Hailu^{1*}, Dube Jara², Alo Edin¹, Abdurazak Awol³, Angefa Ayele¹, Yohannes Fekadu¹, Dereje Endale⁴, Miesa Gelchu¹, Kebebew Lemma¹

1 Department of Epidemiology, School of Public Health, Institute of Health, Bule Hora University, Bule Hora, Ethiopia.

2 Departments of Public Health, College of Health Sciences, Salale University, Fiche, Ethiopia.

3 Departments of Nursing, Institute of Health Sciences, Bule Hora University, Bule Hora, Ethiopia.

4. Department of Nursing, College of Health Sciences and Medicine, Dilla University, Southern Nations, Nationalities and peoples Region, Ethiopia

***Corresponding author:** Digafe Hailu: Department of Epidemiology, School of Public Health, institute of Health, Bule Hora University, Bule Hora, Ethiopia, Tel: +251910707864/+251916409316, [Email: d2014ht@gmail.com](mailto:d2014ht@gmail.com).

Abstract

Background: Ethiopia is one of the nation's most severely impacted by HIV, with an estimated 700,000 people living with HIV/AIDS. Hence, many health facilities were providing second-line antiretroviral therapy, however little was known about viral load suppression among second-line users. This study aimed to assess the proportion of viral load suppression and associated factors among HIV-infected patients on second-line antiretroviral therapy at public health facilities of west Guji, Guji and Borena zones, Southern Ethiopia.

Methods: A facility-based cross-sectional study was conducted among 256 HIV-infected patients on second-line antiretroviral therapy from January 1, 2019, to December 30, 2022, by

using census after obtaining ethical clearance from Bule Hora University ethical review committee. Data were extracted using a structured, pre-tested checklist, entered into the EPI data version 3.1.0, and exported to SPSS version 25 for analysis. The proportion of viral load suppression was determined. A binary logistic regression model was fitted to identify factors associated with viral load suppression. Statistical significance was declared at a 95% confidence interval (CI) with a P-value <0.05.

Results: This study revealed that the proportion of viral load suppression among HIV-infected patients on second-line antiretroviral therapy was 73.8% (95% CI, 68.0–79.1). Those who missed the second-line antiretroviral regimen [AOR = 0.315, 95% CI (0.162–0.612)], a baseline viral load count of <10,000 copies/mm³ [AOR = 2.291, 95% CI (1.216–4.316)], and a baseline body mass index of ≥ 18.5 kg/m² [AOR = 2.438, 95% CI (1.098–5.414)] were significantly associated with viral load suppression.

Conclusions: The proportion of patients with viral load suppression fell below the WHO's and national level. Viral load suppression was significantly influenced by missed second-line antiretroviral doses, a baseline viral load count of <10,000 copies/ml, and a baseline body mass index of ≥ 18.5 kg/m². Hence interventions targeting counseling to patients that missed their antiretroviral therapy, keeping patient's viral load to be less than 10,000 copies/ml through adequate adherence counseling among second-line antiretroviral therapy were recommended.

Keywords: viral load suppression, second-line antiretroviral therapy, southern Ethiopia.

Background: Antiretroviral regimens are recommended for use in order to achieve viral load suppression. The current recommendation for (antiretroviral) ARV regimens is to use three active drugs from two or more drug classes. The most significant indicator of initial and sustained response to ART is viral load (1). It is crucial to switch to an ARV regimen at the right time. Late switching can jeopardize the effectiveness of second-line therapy (2). Monitoring antiretroviral therapy (ART) patients is crucial to guarantee effective therapy, spot adherence issues, and decide whether switching ART regimens is necessary in the event of treatment failure. Since 2016, viral load testing has become the primary method for treatment monitoring, with 20 million viral load tests expected to be performed in low- and middle-income countries by 2020(3). Being on second-line ART, claiming to have poor adherence, and having a previously

suppressed viral load were all independently linked to viral load suppression (4). Viral load monitoring among second-line ART can help reduce the burden on both patients and health care workers by reducing the need for frequent clinic visits (5).

A viral load that is undetectable and less than 50 copies/mL is known as viral load suppression (6). Globally, around 50 percent of HIV-infected patients were virally suppressed (7). Study findings of cohort study in Africa showed that among PLWHA with ART experience and viral suppression, those who moved to tenofovir/lamivudine/dolutegravir (TLD) maintained viral suppression better than those who persisted on other regimens (8). The HIV program in Kenya reported that second-line ART users had a viral load suppression rate of 90% (9). Findings revealed that among 46.8% of HIV patients on second-line ART, 88.2% achieved viral load suppression (4). Ethiopia's findings revealed that second-line ART had a viral load suppression rate of 82.39% (10). There is a paucity of data in Ethiopia and in many resource-limited settings for viral load suppression among HIV-infected patients who received second-line ART. Evidence on the proportion of viral load suppression will provide input to policy and decision makers, program planners, and implementers (both governmental and nongovernmental organizations) for monitoring and evaluation activities (to assess the implementation of national ART guidelines and proper delivery of second-line ART in improving patients' quality of life), to create awareness of the risks, and to take appropriate actions on the factors that promote viral load suppression. This study will also increase the public health body of knowledge and help promote researchers in this area. Moreover, the findings will be used as an additional source of information for further research on related subject matter. In Ethiopia, second-line ART is being implemented in many health facilities; however, there is a single study conducted among second-line ART in the northern part of Ethiopia. This study was limited in scope to further generalize the findings. Therefore, the study is important to fill these research gaps by covering a large study area. Therefore, the aim of this study is to assess the proportion of viral load suppression and associated factors among HIV-infected patients on second-line ART at public health facilities of west Guji, Guji and Borena zones, Southern Ethiopia, from January 1, 2019, to December 30, 2022.

Methods

Study Area, Study Design and Study Period

A facility-based cross-sectional study design was conducted in west Guji, Guji and Borena zones, southern Ethiopia from January 01, 2019 to December 30, 2022. The actual data collection period was from June 20, 2023 to July 10, 2023. West Guji is located 467km, Guji is located 599km and Borena is located 566km away from a capital city of Ethiopia (Addis Ababa) with a total population of 3,776,556. West Guji has 4 hospitals and 42 health centers from these two hospitals and one health center was centers for second-line ART service provision. Guji zone has 4 hospitals and 62 health centers, from these 2 hospitals and 2 health centers were center for second-line ART service provision. Borena zone has 5 hospitals and 45 health centers, from these two hospitals and one health center were providing second-line ART.

Populations

The source populations of this study was all HIV-infected patients on second-line antiretroviral therapy at public health facilities of west Guji, Guji and Borena zones, southern Ethiopia. The study populations was all HIV-infected patients on second-line antiretroviral therapy at public health facilities of west Guji, Guji and Borena zones, Southern Ethiopia from January 1, 2019 to December 30, 2022. All HIV-infected patients' on second-line antiretroviral therapy for more than 6 months of duration at public health facilities of west Guji, Guji and Borena zones, Southern Ethiopia from January 1, 2019 to December 30, 2022 were included in the study whereas those HIV-infected patients, on second-line ART with an unknown viral load test result after the initiation of second-line ART, lost to follow up and those with incomplete charts were excluded from the study.

Sample size Determination

The sample size is calculated by using Epi Info version 7.0 software sample size calculation program for cross sectional study. Considering the following assumptions: 5% level of significance, power of 80% and the different exposure variables like Baseline Viral load count <10,000copies, Isoniazid preventive therapy (yes), and Adherence to ART (good) from previous study. Finally, by adding 10% non-response rate the total sample size was 245.

Sampling method and procedure

Of the ten health facilities expected to provide second-line ART service, eight of them were providing second-line ART in west Guji, Guji, and Borena zones, Southern Ethiopia. These were Bule Hora University Specialized Hospital, Yabelo General Hospital, Moyale Primary Hospital, Moyale Health Center, Negele General Hospital, Adola General Hospital, Adola Health Center, and Shakiso Health Center. From January 1, 2019 through December 30, 2022, a total of 256 HIV-infected patients received second-line antiretroviral therapy. Since the study populations that fulfill the inclusion criteria were below the predicted proportion, all the study populations in the chosen study area were taken into consideration as a sample population. A study unit was selected using census following thorough chart review.

Study variables

The dependent variable of this study was **Viral Load Suppression**.

The independent variables were:

Socio-demographic Factors: -Age, Sex, Marital Status, Educational Status, Residence, Religion, and Types of Health Institutions.

Baseline clinical and laboratory-related factors:

Baseline CD4, Baseline viral load, WHO clinical stages, Baseline weight, Baseline BMI, Functional status, TB at baseline, Other OI at baseline, Admission history.

Treatment-related factors:

Cotrimoxazole preventive therapy, Isoniazid preventive therapy, antiretroviral dose per day, ART regimen, Duration on ART.

Behavioral-related factors:

Adherence level to antiretroviral therapy, Disclosure status, Missing ARV dose.

Operational definitions

Baseline viral load: Viral load result at the start of second-line antiretroviral therapy

Baseline CD4: CD4 count at the start of the second line ART

Baseline clinical stage: WHO stage at the start of the second line ART

Viral load suppression: viral load test results of less than 50 copies/mm³

Baseline Functional Status (11):

Working: able to perform usual work inside or outside the home

Ambulatory: able to perform activities of daily living; not able to work

Bedridden: not able to perform activities of daily living

ART adherence level(12):

Good adherence: average adherence $\geq 95\%$ (patient missing ≤ 2 doses from 30 doses or ≤ 3 doses out of 60 doses).

Fair adherence: average adherence of 85–94% (patient missing 2-4 doses out of 30 doses or 4–9 doses from 60 doses).

Poor adherence: average adherence $< 85\%$ (patient missing ≥ 5 doses from 30 doses or ≥ 10 doses from 60 doses).

Missed second-line antiretroviral therapy: when the patient had poor adherence to ARV regimens.

Data collection tools and procedures

Using a structured checklist, data gatherers retrieved secondary information from the patient's chart, viral load registration logbook, and laboratory request sheets. As a result, all patient charts that contained comprehensive data about those who received second-line antiretroviral therapy were examined. When incomplete data was discovered, the data gatherers attempted to obtain the

information from several data sources (such as the client's chart and follow-up form). Additionally, the data that was most current to the start date of second-line antiretroviral medication was deemed baseline data when clinical parameters and laboratory results (CD4 count and WHO clinical stages) were not found at the start of second-line antiretroviral therapy. Eight nurses with a Bachelor of Science in nursing engaged in the data extraction process as data collectors, and four ART data managers served as supervisors for the three zones.

Data quality assurance

Data quality was assured through the design of a proper data extraction tool. Both data collectors and supervisors received training for one day on the objectives of the study and how to extract data from patient charts, viral load registration logbooks, and laboratory request sheets. The pretest was done by taking 5% of the overall sample at Dilla University General Hospital. During the data collection, a supervisor was assigned to make sure that there was no missed data. The study's investigator was in charge of the entire data extraction process. The reliability (internal consistency) of the tools was measured using Cronbach alpha as the variables were adapted from different literature, and the result was 0.751, indicating that the variables were internally consistent. To check for any errors, missing values, and outliers, the data was cleaned in the end, and analysis was done.

Data processing and analysis

The accuracy and completeness of the data were verified before being entered into Epi Data version 3.1.0 and exported to SPSS version 25 for analysis. The characteristics of the study participants were described using descriptive statistics such as frequencies and percentages for categorical variables and mean and standard deviation for continuous variables. Binary logistic regression analysis was used to identify the association between dependent and independent variables. All independent variables that show association at bivariable logistic regression with a P-value of <0.25 were considered for multivariable logistic regression analysis to identify factors independently associated with viral load suppression after adjusting for possible confounders. The variance inflation factor (VIF), which was used to test for multi-collinearity amongst independent variables, is less than five for all variables used in the analysis. The model passed

the Hosmer-Lemeshow goodness-of-fit test with a score of 0.619. Finally, the AOR determined the level of significance with a 95% confidence interval and a P-value of < 0.05.

Results

Socio-demographic characteristics of the study participants

A total of 256 charts of HIV-infected patients on second-line antiretroviral therapy were reviewed with a response rate of 100%. The majority, 136 (or 53.1%), were married, and 139 (54.3%) of them were women. In terms of educational attainment, the majority of participants 128 (50%) had at least a primary education, whereas 161 (62.9%) of the study's participants reside in an urban region. Nearly half of the research participants 119 or 46.5% received second-line ART in the general hospital. Overall, 162 (63.3%) of the participants belong to the age group of ≥ 36 years (Table 1).

Table 1: Socio-demographic characteristics of HIV-infected patients on second-line antiretroviral therapy at public health facilities of west Guji, Guji and Borena zones, Southern Ethiopia, in 2024 (n = 256)

Variables	Categories	Frequency (n)	Percent (%)
Age in years	6-15	15	5.9
	16-25	32	12.5
	26-35	47	18.4
	≥ 36	162	63.2
Sex	Male	117	45.7
	Female	139	54.3
Marital status	Single	56	21.9
	Married	136	53.1
	Divorced	40	15.6

	Widowed	24	9.4
Educational status	Cannot read and write	79	30.9
	Primary education	128	50.0
	Secondary education and above	49	19.1
Residence	Urban	161	62.9
	Rural	95	37.1
Religion	Orthodox	97	37.9
	Muslim	55	21.5
	Protestant	91	35.5
	Others	13	5.1
Types of health institutions	Health Center	44	17.2
	Primary Hospital	12	4.7
	General Hospital	119	46.5
	Specialized Hospital	81	31.6

Baseline clinical and laboratory characteristics of the study participants

More than half 177 (69.1%) of study participants had a baseline CD4 count of >200 cells/mm³, whereas 129 (50.4%) participants had a baseline viral load count of >=10,000 copies. The majority of the respondents, 167 (65.2%), were stage I RVI, and 200 (78.1%) were working. With regard to baseline weight, 149 (58.2%) of the study participants were >50 kg (Table 2).

Table 2: Baseline clinical and laboratory-related characteristics of HIV-infected patients on second-line ART at public health facilities of west Guji, Guji and Borena zones, Southern Ethiopia, in 2024 (n = 256)

Variables	categories	Frequency (n)	Percent (%)
CD4 cell count	≤200cells/mm ³	79	30.9
	>200cells/mm ³	177	69.1

Viral load count	<10,000 copies/mm ³	127	49.6
	≥10,000 copies/mm ³	129	50.4
WHO RVI stage	Stage I	167	65.2
	Stage II	19	7.4
	Stage III	57	22.3
	Stage IV	13	5.1
Weight in kg	≤20kg	14	5.5
	21-50kg	93	36.3
	>50kg	149	58.2
BMI in kg/m²	<18.5kg/m ²	93	36.3
	≥18.5kg/m ²	163	63.7
Functional status	Working	200	78.1
	Ambulatory	38	14.8
	Bedridden	18	7.1
Tuberculosis(TB)	No	231	90.2
	Yes	25	9.8
Other OI	No	232	90.6
	Yes	24	9.4
Admission history	No	220	85.9
	Yes	36	14.1

Treatment-related characteristics of the study participants

The majority, 218 (85.2%) of study participants, used CPT, and 202 (78.9%) of them used IPT. Nearly half of respondents, 116 (45.3%), were on AZT-3TC-ATV/r. Almost all 230 (89.8%) of the patients took their second-line ART twice daily (Table 3).

Table 3: Treatment-related characteristics of HIV-infected patients on second-line ART at public health facilities of west Guji, Guji and Borena zones, Southern Ethiopia, in 2024 (n = 256)

Variables	Categories	Frequency (n)	Percent (%)
CPT	No	38	14.8
	Yes	218	85.2
IPT	No	54	21.1
	Yes	202	78.9
Second-line ART doses per day	Once	26	10.2
	Twice	230	89.8
Second-line ART	AZT-3TC-LPV/r	15	5.9
	AZT-3TC-ATV/r	116	45.3
	TDF-3TC-LPV/r	24	9.4
	TDF-3TC-ATV/r	75	29.3
	ABC-3TC-LPV/r	14	5.5
	ABC-3TC-DTG(5M)	12	4.7
Duration on second-line ART	≤24 months	59	23.0
	>24 months	197	77.0

CPT: Cotrimoxazole preventive therapy; **IPT:** Isoniazid preventive therapy.

Behavioral-related characteristics of the study participants

The majority of research participants, 181 (70.7%), had good adherence to second-line antiretroviral medication. Seventy-seven percent of research participants told their families they were HIV positive. Two-thirds (75.0%) of the subjects did not miss their second-line antiretroviral therapy (Table 4).

Table 4: Behavioral-related characteristics of HIV-infected patients on second-line ART at public health facilities of west Guji, Guji and Borena zones, Southern Ethiopia, in 2024 (n = 256)

Variables	Categories	Frequency(n)	Percent (%)
Adherence level to second-line ART	Good	181	70.7
	Fair	16	6.3
	Poor	59	23.0

HIV Disclosure status	No	59	23.0
	Yes	197	77.0
Missed second-line ARV doses	No	192	75.0
	Yes	64	25.0

Proportion of viral load suppression

The proportion of viral load suppression among HIV-infected patients who received second-line antiretroviral therapy was 73.8% [95% CI (68.0–79.1)], which is nearly two-thirds of the study populations (Figure 1).




Figure 1: Proportion of viral load suppression among HIV-infected patients on second-line antiretroviral therapy at public health facilities of west Guji, Guji and Borena zones, Southern Ethiopia, in 2024 (n = 256)

Factors associated with viral load suppression

A bi-variable logistic regression was carried out to identify potential variables for a multivariable logistic regression. Age, marital status, residence, missed second-line antiretroviral doses, baseline viral load count, baseline weight, baseline BMI, and duration of second-line antiretroviral therapy were found to have a significant association with the outcome variable at a p-value less than 0.25 and were considered candidate variables for multivariable logistic regression. Accordingly, these variables were selected as candidates for the initial multivariable logistic regression, and three variables: - missed second-line antiretroviral doses, a baseline viral load count of <10,000 copies/mm³, and a baseline body mass index of ≥18.5 kg/m² were found to have a statistically significant association with the outcome variable at a p-value of less than 0.05 in the multivariable analysis. Those participants who missed their second-line antiviral medications were 68.5% less likely to experience viral load suppression than those who did not miss their medication [AOR = 0.315, 95% CI (0.162–0.612)]. Study participants with a baseline viral load count of <10,000 copies/mm³ had a 2 times higher chance of achieving viral load suppression compared to those with a baseline viral load count of ≥10,000 copies/mm³ [AOR = 2.291, 95% CI (1.216–4.316)]. Similarly, participants with a baseline body mass index of ≥18.5 kg/m² had about a two-fold increased chance of achieving viral load suppression than those with a baseline body mass index of <18.5 kg/m² [AOR = 2.438, 95% CI (1.098–5.414)] (Table 5).

Table 5: Bi-variable and multivariable analysis of factors associated with viral load suppression among HIV-infected patients on second-line antiretroviral therapy between January 1, 2019 and December 30, 2022, at public health facilities of west Guji, Guji and Borena zones, Southern Ethiopia, in 2024 (n = 256)

Variables	Categories	Viral load status		COR(95% CI)	AOR(95% CI)	P-value
		Suppressed(n)	Unsuppressed(n)			
Age in years	6-15	9	6	0.398(0.133-1.197)	0.747(0.133-4.178)	0.740
	16-25	18	14	0.342(0.154-0.756)	0.384(0.114-1.310)	0.127
	26-35	34	13	0.695(0.331-1.460)	0.679(0.300-1.536)	0.353

	≥36	128	34	1	1	
Marital status	Single	35	21	0.152(0.032-0.711)	0.354(0.052-2.394)	0.287
	Married	103	33	0.284(0.063-1.271)	0.251(0.049-1.288)	0.097
	Divorced	29	11	0.240(0.048-1.193)	0.207(0.036-1.188)	0.077
	Widowed	22	2	1	1	
Residence	Urban	123	38	1.422(0.806-2.511)	1.439(0.756-2.741)	0.268
	Rural	66	29	1	1	
Missed second-line ART	No	153	39	1	1	
	Yes	36	28	0.328(0.179-0.601)	0.315(0.162-0.612)	0.001
Duration on second-line ART	≤24months	38	21	0.551(0.295-1.032)	0.515(0.257-1.031)	0.061
	>24months	151	46	1	1	
Baseline weight in kg	≤20kg	6	8	0.222(0.072-0.683)	0.562(0.104-3.034)	0.503
	21-50kg	68	25	0.804(0.443-1.461)	1.656(0.714-3.837)	0.240
	>50kg	115	34	1	1	
Baseline viral load count	<10,000 copies	103	24	2.146(1.207-3.816)	2.291(1.216-4.316)	0.010
	≥10,000 copies	86	43	1	1	
Baseline body mass index	<18.5kg/m ²	60	33	1	1	
	≥18.5kg/m ²	129	34	2.087(1.182-3.684)	2.438(1.098-5.414)	0.029

The Arabic number (**1**) represents “reference”

Discussions

This study was conducted to determine the proportion of viral load suppression and associated factors among HIV-infected patients on second-line antiretroviral therapy. The findings of the

study suggest that the overall viral load suppression among HIV-infected patients on second-line antiretroviral therapy was 73.8% (95% CI: 68.0–79.1). This finding is consistent with studies conducted in the Ehlanzeni district of South Africa (74%), Uganda (75.8%), Kumasi, Ghana (76.1%), and the East Shewa zone of Oromia, Ethiopia (72%)(13-16). However, this finding is lower than those of studies conducted in the USA (86%)(17), Buenos Aires, Argentina (87.3%)(18), Cameroon (88.2% and 94.55%)(19, 20), Uganda (81%, 85%, & 85.7%)(21-23), Bamako, Mali (100%)(24), Mazowe, Zimbabwe (94.4%)(25), Tanzania (91.5%)(26), South Africa (77% and 77.2%)(27, 28), Kenya (80% and 90%) (29, 30), Ethiopia (82% and 82.39%) (10, 31). The ambitious 95-95-95 approach put forth by USAID, WHO, and UNAIDS to achieve 95% viral load suppression by 2030 is too far from the current results (5, 32). This discrepancy could be attributed to a variety of factors, including differences in the resources available to facilities and the study's exclusive focus on second-line antiretroviral therapy.

In contrast to the above, the current finding is higher than the findings reported from the studies done in the United States (30.51%), Zimbabwe (30%), Johannesburg, South Africa (56.5%), Kampala, Uganda (66.4%), Gomba district, rural Uganda (10%), Haut-Katanga and Kinshasa Provinces of the Democratic Republic of the Congo (56.4%), Wollo, Northeast Ethiopia (66.4%), Bahir Dar, Ethiopia (57.1%), and the Public Hospitals of Hawasa City Administration, Ethiopia (40.9%)(11, 32-39). This discrepancy could be due to the fact that different donors are currently working in Ethiopia in collaboration with government to achieve targets in viral load suppression rate for 2030.

The current study found that among HIV-infected patients on second-line antiretroviral therapy and those who missed second-line antiretroviral regimens, a baseline viral load count of <10,000 copies/mm³ and a baseline body mass index of ≥ 18.5 kg/m² were statistically significant factors associated with viral load suppression. The findings of the study showed that HIV-infected individuals who missed second-line antiretroviral therapy were less likely to experience viral load suppression than HIV-infected individuals who did not miss their second-line antiretroviral therapy. This may be due to the fact that skipping antiretroviral doses might cause HIV to change its form, impairing the effectiveness of therapy by making drugs less effective and increasing the risk of developing drug resistance. When the ARV regimen is missed, HIV has a chance to grow quickly and impair the immune system, which keeps the viral load high(40). As a result, an HIV-

infected patient who follows the recommended HIV treatment regimen can stay healthy and prevent HIV transmission to sex partners(41). This result is consistent with studies done in India, San Francisco, resource-limited settings, Uganda, Malawi, Zimbabwe, and South Africa (42-47).

This study demonstrates that baseline viral load count is a significant factor that influences the viral load suppression process. HIV-infected patients on second-line antiretroviral therapy and had a baseline viral load count of $<10,000$ copies/mm³ show a 2-fold increased chance of achieving viral load suppression as compared to those who had a baseline viral load count of $\geq 10,000$ copies/mm³. This disparity between the groups is brought about by the fact that when the viral load is low at baseline, the virus is likely not actively reproducing as quickly, immune system damage may be reduced, and HIV consequences may be less common, all of which contribute to a lower HIV reservoir in the blood(48). This finding is in line with research from Taiwan, Uganda, Wollo, Bahir Dar, and Arba Minch, Ethiopia(11, 35, 37, 49-52).

Viral load suppression was significantly influenced by body mass index (BMI). Patients on second-line antiretroviral medication and whose baseline BMI was ≥ 18.5 kg/m² had a higher chance of experiencing viral load suppression compared to patients whose baseline BMI was <18.5 kg/m². This can be explained by the fact that when a person's BMI is low or less than 18.5 kg/m², as compared to a normal BMI, they are more susceptible to malnutrition and compromised immune function, which raises their risk of contracting a number of diseases. As a result, viral load levels will increase when the immune system is weak or sick, limiting the likelihood of viral load suppression(53). Patients with a low BMI should therefore get appropriate dietary therapy and counseling in accordance with established treatment protocols. This finding is in line with the research conducted in South Wollo, Ethiopia(49).

Limitations of the study

Secondary data makes it challenging to locate patient information quickly and to get adequate variables from the charts.

Due to the small number of people taking second-line antiretroviral therapy, a wider range of age groups (including both children and adults) was chosen to increase the number of participants.

Conclusions

The proportion of viral load suppression was less than what the WHO and UNAIDS strategy had suggested for 2030. A missed second-line antiretroviral regimen, a baseline viral load count < 10,000 copies/mm³, and a baseline body mass index ≥ 18.5 kg/m² were found to have a statistically significant and independent association with viral load suppression. Hence interventions targeting providing counseling to patients that missed their therapy, keeping patient's viral load to be less than 10,000 copies/ml through adequate adherence counseling among second-line antiretroviral therapy were recommended.

Abbreviations

AIDS: Acquired Immunodeficiency Syndrome; ART: Antiretroviral Therapy; ARV: Antiretroviral; BMI: Body Mass Index; CPT: Co-trimoxazole Preventive Therapy; DTG: Dolutegravir, DVS: Durable Viral Suppression; FDC: Fixed Dose Combination; HAART: Highly Active Anti-retroviral Therapy; HIV: Human Immunodeficiency Virus; HTS: HIV Testing Service; IL: Interleukin; IPT: Isoniazid Preventive Therapy; MDGs: Millennium Development Goals; NRTI: Non Reverse Transcriptase Inhibitor; OI: Opportunistic Infection; PI: Protease Inhibitor; PLWHA: People Living With HIV/AIDS; RNA: Ribonucleic Acid; RVI: Retroviral Infection; TB: Tuberculosis; tVR: transient Viral Rebound; VIF: Variance Inflation Factor; VLS: Viral Load Suppression.

Ethical approval

To grant access to patient records, Bule Hora University Specialized Hospital, Yabelo General Hospital, Moyale Primary Hospital, Moyale Health Center, Negele General Hospital, Adola General Hospital, Adola Health Center, and Shakiso Health Center received ethical clearance from ethical review committee of Bule Hora University, the Institute of Health with reference number of BHU/IOH/SPH/0039/2015.

Consent of participants

Data were taken from the patient's chart, laboratory request sheets, and high viral load registration logbook after obtaining consent from ART focal person of each health facility. As the data was obtained from patient records and its source was secondary data, obtaining consent from study participants were not possible. Therefore, data confidentiality was maintained

throughout the study, and in accordance with the Helsinki Declaration, the data will not be utilized for any other purposes.

Consent for publication

Not applicable.

Availability of data and materials

All relevant data are available from the corresponding author upon reasonable request

Competing interests

The authors declare that they have no competing interests

Funding

Bule Hora University

Authors' Contribution

DH: Designed and participated in data collection, conducted the data analysis and interpretation, developed the first draft and revised subsequent drafts. DJ: Advised on the conception of study area, data analysis and interpretation reviewed and commented on successive drafts. AE: Advised on the data analysis and interpretation and commented on successive drafts and reviewed and edited. AbA: Advised on the conception of study area, data analysis and interpretation reviewed and commented on successive drafts. AA: Advised on the data analysis and interpretation and commented on successive drafts and reviewed. YF: Participated in data collection and developed the first draft and revised subsequent drafts. DE: Advised on the conception of study area, data analysis and interpretation. Reviewed, edited and commented on successive drafts. MG: Advised on the successive drafts reviewed and participated in analysis. KL: Advised on the conception of study area, data analysis and interpretation reviewed and commented on successive drafts. All authors reviewed and approved the final manuscript.

Acknowledgments

The authors acknowledge Bule Hora University Institute of Health, School of Public Health, for the overall facilitation. We would like to thank the data collectors and supervisors for their contribution to materializing data collection activities and sincerely thanking Meriyan

Abdulkadir, Kasu Dade, and Firomsa Abera for their assistance in sharing data and up-to-date information about second-line antiretroviral therapy.

ORCID iD

Digafe Hailu Teka **iD** <https://orcid.org/0009-0009-5836-1697>

References

1. OARAC. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. <https://clinicalinfohiv.gov/en/guidelines/adult-and-adolescent-arv>. 2022.
2. evidence to action U, unicef, WHO. National AIDS Control Organisation (NACO). <https://wwwaidsdatahub.org/taxonomy/term/377>. 2021.
3. WHO. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring 2021.
4. Djiyou ABD, Penda CI, Madec Y, Ngondi GD, Moukoko A, Varloteaux M, et al. Viral load suppression in HIV-infected adolescents in cameroon: towards achieving the UNAIDS 95% viral suppression target. *BMC Pediatr*. 2023;23(1):119.
5. USAID. Reaching the Third 95: Viral Load Suppression among Key Population Individuals Living with HIV. <https://wwwfhi360org/sites/default/files/media/documents/linkages-hiv-viral-load-suppressionpdf>.
6. FMOH. National guidelines for comprehensive HIV prevention, care and treatment 2022.
7. UNAID. Undetectable =untransmittable public health and HIV viral load suppression https://wwwunaidsorg/sites/default/files/media_asset/undetectable-untransmittable_enpdf. 2018.
8. Allahna Esber P M, Nicole Dear, MPH, Neha Shah, MD, MPH, Hannah Kibuuka, MBChB, Jonah Maswai, MBChB, MPH, John Owuoth, MBChB, Valentine Singoei, MBChB, Emmanuel Bahemana, MD, Michael Iroezindu, MB, BS, MPH, Trevor A. Crowell, MD, PhD, Christina S. Polyak, MD, MPH, Joseph S. Cavanaugh, MD, and Julie A. Ake, MD, MSc., Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study. *wwwjaidscom*. 2022.
9. Rose Nyaboke HOR, Taylor Lascko, Patrick Awuor, Elvis Kirui, Emily Koech, Immaculate Mutisya, Carol Ngunu and Rebecca Wangusi. Factors associated with adherence and

viral suppression among patients on second line antiretroviral therapy in an urban HIV program in Kenya. *SAGE Open Medicine*. 2023;11:1–9.

10. Wedajo SD, G. Deribew, A. Ambaw, F. Rate of Viral Re-Suppression and Retention to Care Among PLHIV on Second-Line Antiretroviral Therapy at Dessie Comprehensive Specialized Hospital, Northeast Ethiopia: A Retrospective Cohort Study. *HIV AIDS (Auckl)*. 2021;13:877-87.

11. Minyichil B. Viral Load Suppression and its Predictor Among Hiv Seropositive People Who Receive Enhanced Adherence Counseling at Public Health Institutions in Bahir Dar, Northwest Ethiopia. Retrospective Follow-Up Study. <http://dSPACE.org>. 2022.

12. FMOH. National Guidelines for Comprehensive HIV Prevention, Care and Treatment 2022.

13. Huibers MHW, Kityo C, Boerma RS, Kaudha E, Sigaloff KCE, Balinda SN, et al. Long-term virological outcomes, failure and acquired resistance in a large cohort of Ugandan children. *J Antimicrob Chemother*. 2019;74(10):3035-43.

14. Okonji EFvW, B.Mukumbang, F. C.Hughes, G. D. Determinants of viral suppression among adolescents on antiretroviral treatment in Ehlanzeni district, South Africa: a cross-sectional analysis. *AIDS Res Ther*. 2021;18(1):66.

15. Stephen Opoku SAS, Nana Kwame Ayisi-Boateng, Anthony Kwame Enimil benezer Senu, Richard Owusu Ansah, Bismark Dankwah Aning, Diana Atsieno Ojuang, Doreen Nafula Wekesa, Fatima Osman Ahmed, Chidinma B. Okeke and Ama Darkoaa Sarfo. Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana. *AIDS Research and Therapy*. 2022.

16. Yirtaw JHAaTG. Time to viral load suppression and its associated factors in cohort of patients taking antiretroviral treatment in East Shewa zone, Oromiya, Ethiopia, 2018. *BMC Infectious Diseases*. 2019.

17. al. Ne. HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study. *HHS Public Access*. 2019.

18. Socias MER, F. Lapadula, P. Medrano, M. Paz, D. Stern, L. Lambierto, A. Pryluka, D. Treatment as prevention in resource-limited settings: is it feasible to maintain HIV viral load suppression over time? *J Infect Dev Ctries*. 2013;7(8):593-9.

19. Armando B. D. Djiyou CIP, Yoann Madec, Grace Dalle Ngondi, Astrid Moukoko, Marie Varloteaux, Laure-Amélie de Monteynard, Cecile Moins, Carole Else Eboumbou Moukokoand Avelin F. Aghokeng. Viral load suppression in HIV-infected adolescents in cameroon: towards achieving the UNAIDS 95% viral suppression target. *BMC pediatrics* 2023.
20. Awungafac GA, E. T. Fualefac, A. Takah, N. F. Agyingi, L. A. Nwobegahay, J. Ondoa, P. Njukeng, P. A. Viral load testing and the use of test results for clinical decision making for HIV treatment in Cameroon: An insight into the clinic-laboratory interface. *PLoS One*. 2018;13(6):e0198686.
21. Dathan M Byonanebye FCS, Jackson Katende , Alex Bakenga , Irene Arinaitwe , Peter Kyambadde , Patrick Musinguzi , Irene Andia Biraro , Pauline Byakika-Kibwika , Moses R Kamy. High viral suppression and low attrition in healthy HIV-infected patients initiated on ART with CD4 above 500 cells/ μ L in a program setting in Uganda. *Afr Health Sci*. 2020.
22. Gordon TPT, M.Mugisha, M. K.Herbert, A. E. Factors associated with HIV viral suppression among adolescents in Kabale district, South Western Uganda. *PLoS One*. 2022;17(8):e0270855.
23. Paul Wakooko YGaJNW. Viral load Suppression and Associated Factors among HIV Patients on Antiretroviral Treatment in Bulambuli District, Eastern Uganda: A Retrospective Cohort Study. *Infectious Diseases*. 2020.
24. Hakim AJC, K. Patnaik, P. Telly, N. Ballo, T. Traore, B. Doumbia, S. Lahuerta, M. An urgent need for HIV testing among men who have sex with men and transgender women in Bamako, Mali: Low awareness of HIV infection and viral suppression among those living with HIV. *PLoS One*. 2018;13(11):e0207363.
25. Nyakura JS, H. D.Ade, S.Mushavi, A.Mukungunugwa, S. H.Chimwaza, A.Owiti, P.Senkoro, M. Mugurungi, O. Viral load testing among women on 'option B+' in Mazowe, Zimbabwe: How well are we doing? *PLoS One*. 2019;14(12):e0225476.
26. Rugemalila JK, D.Kunambi, P.Mizinduko, M.Sabasaba, A.Masoud, S.Msafiri, F.Mugusi, S.Mutagonda, R. Mlunde, L. Amani, D.Mboya, E.Mahiti, M.Ruhago, G.Mushi, J.Sambu, V.Mgomella, G.Jullu, B.Maokola, W.Njau, P.Mutayoba, B.Barabona, G.Ueno, T.Pembe, A.Nagu, T.Sunguya, B.Aboud, S. HIV virologic response, patterns of drug resistance mutations and correlates among adolescents and young adults: A cross-sectional study in Tanzania. *PLoS One*. 2023;18(2):e0281528.

27. Fox MPP, S.Huber, A. N.Murphy, J.Phokojoe, M.Gorgens, M.Rosen, S.Wilson, D.Pillay, Y.Fraser Hurt, N. Adherence clubs and decentralized medication delivery to support patient retention and sustained viral suppression in care: Results from a cluster-randomized evaluation of differentiated ART delivery models in South Africa. *PLoS Med.* 2019;16(7):e1002874.
28. Matthew Fox PI, Lawrence Long, Mhairi Maskef, IanSanne, I. Successful Second Line Antiretroviral Therapy with High Rates ofSurvival, Immune Reconstitution and Virologic suppression in aLarge Urban Clinic in Johannesburg, South Africa
29. Anne Mwangi BvW. Factors Associated with Viral Suppression Among Adolescents on Antiretroviral Therapy in Homa Bay County, Kenya: ARetrospective Cross-Sectional Study. *HIV/AIDS - Research and Palliative Care* 2021.
30. Rose Nyaboke HOR, Taylor Lascko, Patrick Awuor, Elvis Kirui, Emily Koech, Immaculate Mutisya, Carol Ngunu and Rebecca Wangusi. Factors associated with adherence and viral suppression among patients on secondline antiretroviral therapy in an urban HIV program in Kenya. *SAGE Open Medicine.* 2023.
31. Melku MA, G.Teketel, A.Asrie, F.Yalew, A.Biadgo, B.Kassa, E.Damtie, D.Anlay, D. Z. Immunological status and virological suppression among HIV-infected adults on highly active antiretroviral therapy. *Environ Health Prev Med.* 2020;25(1):43.
32. WHO. HIV and AIDS key facts <https://www.who.int/news-room/fact-sheets/detail/hiv-aids> gclid=CjwKCAjwq4imBhBQEiwA9Nx1BtjTr3A0g2KpQwql1ypcgcu_L2-7H3FB8_4hLl_0CGDV8u_XjEwtGBoCPx8QAvD_BwE. 2023.
33. Abenezer Abraham Anito TLL, Eskinder Woticha , Fithamlak Solomon. Magnitude of Viral Load Suppression and Associated Factors among Clients on Antiretroviral Therapy in Public Hospitals of Hawassa City Administration, Ethiopia. *HIV/AIDS - Research and Palliative Care* 2022.
34. Balachandra S, Rogers JH, Ruangtragool L, Radin E, Musuka G, Oboho I, et al. Concurrent advanced HIV disease and viral load suppression in a high-burden setting: Findings from the 2015-6 ZIMPHIA survey. *PLoS One.* 2020;15(6):e0230205.
35. Catherine Nakaye NM, Denis Mawanda, Hajira Kataike, Hellen Kaganzi, Grace Miriam Ahimbisibwe, Gerald Bright Businge, Raymonds Crespo Kyambadde, and Rita Nakalega. Viral load suppression after intensive adherence counselling among adult people living with HIV at

- Kiswa health centre, Kampala: a retrospective cohort study. Secondary data analysis. *AIDS Research and Therapy*. 2023;20:18.
36. Fearon ET, S.Mokoena, C.Moodley, K.Smith, A. D.Bourne, A.Weatherburn, P.Palaneephillips, T. HIV testing, care and viral suppression among men who have sex with men and transgender individuals in Johannesburg, South Africa. *PLoS One*. 2020;15(6):e0234384.
37. Gedefaw Diress SD, Birhan Alemnew , Seteamlak Adane,and Amanuel Addisu. Viral Load Suppression after Enhanced Adherence Counseling and Its Predictors among High Viral Load HIV Seropositive People in North Wollo Zone Public Hospitals, Northeast Ethiopia, 2019: Retrospective Cohort Study. Hindawi. 2020.
38. Kahana SYJ, R. A.Bruce, D.Fernandez, M. I.Hightow-Weidman, L. B.Bauermeister, J. A.Adolescent Medicine Trials Network for, H. I. V. Aids Interventions. Structural Determinants of Antiretroviral Therapy Use, HIV Care Attendance, and Viral Suppression among Adolescents and Young Adults Living with HIV. *PLoS One*. 2016;11(4):e0151106.
39. Shah GHM, L.Etheredge, G. D.Waterfield, K. C.Ikhile, O.Beni, R.Engetele, E.Mulenga, A. HIV Viral Suppression among People Living with HIV on Antiretroviral Therapy in Haut-Katanga and Kinshasa Provinces of Democratic Republic of Congo. *Healthcare (Basel)*. 2021;10(1).
40. Fund MHA. HIV Treatment. <https://www.hiv.gov/hiv-basics/staying-in-hiv-care/hiv-treatment/taking-your-hiv-medications-every-day/>. 2023.
41. CDC. HIV Treatment as Prevention. <https://www.cdc.gov/hiv/risk/art/index.html>. 2023.
42. Jaya Chakravarty SS, Ankita Chourasia, Pallav Narayan Singh, Swarali Kurle, Srikanth P. Tripathy, Devidas N Chaturbhuj, Madhukar Rai, Amit Kumar Agarwal, Rabindra Nath Mishra & Ramesh S. Paranjape Outcome of patients on second line antiretroviral therapy under programmatic condition in India. *BMC Infectious Diseases*. 2015.
43. Julia K. Rohr PI, C. Robert Horsburgh, Rebecca Berhanu, Kate Shearer,Mhairi Maskew, Lawrence Long, Ian Sanne, Jean Bassett6 , Osman Ebrahim, Matthew P. Fox. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. *PLoS ONE*. 2016.
44. Patience Atuhaire SH, Nonhlanhla Yende-Zuma,Jim Aizire,Lynda Stranix-Chibanda,Bonus Makanani,Beteniko Milala,Haseena Cassim,Taha Taha,Mary Glenn Fowler,.

Factors associated with unsuppressed viremia in women living with HIV on lifelong ART in the multi-country US-PEPFAR PROMOTE study: A cross-sectional analysis. *plos one* 2019.

45. Richard Court RL, Annemie Stewart, Henry Sunpath, Richard Murphy, Philip Winternheimer, Mashuda Ally and Gary Maartens. Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study in south Africa. *BMC Infectious Diseases*. 2014.

46. Sheri D. Weiser CY, David Guzman, Edward A. Frongillo, Elise D. Riley, David R. Bangsberg, and Margot B. Kushe. Food insecurity and HIV clinical outcomes in a longitudinal study of urban homeless and marginally housed HIV-infected individuals San Fransisco. *HHS Public Access*. 2018.

47. Thiago S. TORRES LJH, Alberto M. LA ROSA, Lu ZHENG, Sandra W. CARDOSO,1 Godwin ULAYA, Nazim AKOOJEE, Dileep KADAM,Ann. C. COLLIER, Michael D. HUGHES. Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings. *AIDS Care*. 2021.

48. Care IAoPoA. viral load fact sheet. <https://www.iapac.org/fact-sheet/viral-load/#:~:text=A%20lower%20HIV%20viral%20load,copies%20per%20milliliter%20of%20blood>. 2023.

49. Dagnachew Melak SW, Reta Dewau. Time to Viral Re-suppression and Its Predictors among Adults on Second-Line Antiretroviral Therapy in South Wollo Zone Public Hospitals: Stratified Cox Model. *HIV/AIDS - Research and Palliative Care* 2023.

50. Dathan M Byonanebye FCS, Jackson Katende, Alex Bakenga Irene Arinaitwe, Peter Kyambadde, Patrick Musinguzi, Irene Andia BiraroPauline Byakika-Kibwika, Moses R Kanya. High viral suppression and low attrition in healthy HIV-infected patients initiated on ART with CD4 above 500 cells/ μ L in a program setting in Uganda. *African Health Sciences* 2020.

51. Sultan Hussen MM, Bitew Mekonnen, Manaye Yihune, Mulugeta Shegaze, Negussie Boti, Mohammed Shure. Predictors of Time to Viral Load Suppression of Adult PLWHIV on ART in Arba Minch General Hospital: A Follow up Study. *Ethiop J Health Sci* 2019.

52. Szu-Wei Huang M-CS, Wen-Hung Wang, Wei-You Li, Jen-Hsien Wang, Cheng-Yin Tseng6, Po-Yu Liu, Lih-Shinn Wang, Yu-Lin Lee, Yi-Ming Arthur Chen, Chun-Yuan Lee, Po-Liang Lu and Sheng-Fan Wang. High prevalence of HIV-1 transmitted drug resistance and

factors associated with time to virological failure and viral suppression in Taiwan. *J Antimicrob Chemother.* 2022.

53. [channel](#) [bh.](#) [body](#) [mass](#) [index\(BMI\).](#)

<https://www.betterhealth.vic.gov.au/health/healthy-living/body-mass-index-bmi>. 2022.